A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer.

Purpose: To explore the efficacy and safety of pyrotinib in a real-world setting in a population with HER2-positive advanced breast cancer, subgroup analysis was conducted based on different clinicopathological features to further explore the general characteristics of patients, tumor nature, and the effect of various lines of treatment before patients started pyrotinib on the efficacy of pyrotinib in the real-world study.

Methods: The clinical pathological characteristics, drug efficacy and related adverse reactions of HER2-positive MBC patients treated with pyrotinib in six hospitals in Southeast Zhejiang Province from February 2018 to December 2023 were collected and analyzed retrospectively.

Results: A total of 342 patients with HER2-positive MBC were enrolled.

Real-World Analysis of the Efficacy and Adverse Events of T-DM1 in Chinese Patients With HER2-Positive Breast Cancer.

Purpose: This study efforts to explore the association of adverse events (AEs) with efficacy in HER2-positive breast cancer patients treated with TDM1.

Methods And Materials: This retrospective study included women diagnosed with HER2+ BC treated with TDM1 from January 2012 to December 2023. Event-free survival (EFS) was the endpoint.

The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study.

Purpose: This study efforts to explore the association between sarcopenia, an age-related decline in muscle mass and physical function, and clinical outcomes in women with triple-negative breast cancer (TNBC).

Methods And Materials: This retrospective study included women diagnosed with TNBC who received breast surgery from December 2012 to December 2018. Skeletal muscle mass index (SMI) is utilized to evaluate sarcopenia, which was quantified by the cross-sectional area of muscle at the twelfth thoracic vertebra (T12).

Breast metastasis from lung adenocarcinoma: a case report and review of the literature.

Lung cancer (LC) is one of the most lethal and most prevalent malignant tumors, and lung adenocarcinoma (LUAD) is the most common pathological type of lung cancer. Breast cancer (BC) is the most common cancer worldwide, but metastases to the breast from extramammary neoplasms are rare, especially from the lung. Early diagnosis and differentiation of primary from metastatic breast carcinoma are essential.